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http:WHAT THIS PAPER ADDS
Catheter-directed foam sclerotherapy (CDFS) is a safe and cost-effective method to treat incompetent saphe-
nous veins. In order to improve occlusion rates different techniques to pre-treat the targeted vein for a better
contact with the sclerosant agent have been described. Applying tumescent local anesthesia (TLA) is a standard
procedure in endovenous thermal procedures and is known to not only provide anesthesia and disperse the
generated heat, but also to ensure minimal vessel diameter by compressing the target vein concentrically. This
trial is the ﬁrst to investigate the combination of CDFS and TLA.Objectives: The aim of this study was to evaluate occlusion rates of great saphenous veins (GSV) with a diameter
between 5e10 mm that received a pre-treatment size reduction via perivenous tumescent application (TA)
followed by catheter-directed foam sclerotherapy (CDFS).
Methods: A prospective blinded randomized clinical trial comparing the occlusion rates of GSV at 1-, 6-, and 12-
month follow-up. Fifty patients were included and randomized into two groups. CDFS was performed accessing
the GSV at knee level and applying 8 mL of 2% polidocanol-foam (EasyFoam) while the catheter was withdrawn.
Strictly perivenous TA was performed in group 1 before applying the sclerosant agent. Occlusion rates and clinical
scores were assessed by blinded examiners.
Results: After 12 months in group 1 full occlusion was achieved in 73.9%, partial occlusion in 8.7%, and 17.4%
were classiﬁed as treatment failure. In group 2, 75% of the targeted GSV were fully occluded, 20% were partially
occluded, and 5% were diagnosed as treatment failure. Both groups showed a signiﬁcant reduction of the vein
diameter. Patient’s tolerance and satisfaction with the treatment was high in both groups.
Conclusion: No beneﬁt could be found using additional TA to reduce the vein diameter before the treatment.
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insufﬁciencyINTRODUCTION
Foam sclerotherapy (FS) is known to be a safe and cost-
effective treatment for varicose veins.1 Occlusion rates of
varicose veins 1e2 years after treatment with foam
sclerotherapy vary between 53 and 80%.2 Best results, in
terms of occlusion rates, were shown for small-caliber
varicose veins (<5 mm), such as tributaries.3 Higher oc-
clusion rates, especially in terms of long-term results and
for large caliber truncal veins, are desirable. Studies could
show that for adequate occlusion either a high sclerosant
concentration or the right amount of volume according torresponding author. B. Kahle, Department of Dermatology, University
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//dx.doi.org/10.1016/j.ejvs.2013.10.017vein diameter is relevant.2,4e8 Tables of concentrations
according to vein diameters were described by Hamel-
Desnos et al. in 2006.5 Recommendations of Polidocanol
concentrations in FS are given in European guidelines.6 It is
also known, that by exceeding a certain amount of foam the
risk of side effects, such as hyperpigmentation, inﬂamma-
tion, and especially thromboembolic complications,
increases.9,10 To reduce the risk of complications sclero-
therapy guidelines do not recommend exceeding a
maximum volume of 10 mL per session.6,9,11 To achieve
optimum contact of the sclerosant agent with the endo-
thelium in large-caliber varicose veins without exceeding
the recommended maximum amount of sclerosant agent,
minimizing the targeted vein before the treatment could
prove to be an option. It could be shown that sclerosant
agents are rapidly deactivated by blood proteins.12 There-
fore, as perivenous tumescence makes less contact of the
foam with the blood, it could be beneﬁcial. Perivenous
Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Men and women
aged 18e89 years
Incompetent great
saphenous vein (GSV)
Diameter 5e10 mm,
measured 3 cm distal to
the sapheno-femoral
junction in supine position
Reﬂux >1 s
Compressibility of GSV
Intact deep vein system
Given informend consent
Symptomatic patent
foramen ovale
Pregnancy
Arterial disease of the
lower limbs (ankle-brachial
index <0.8)
Severe cardiovascular disease
Acute thromboembolic diseases
Fever
Psychiatric disorders
Known allergy to
polidocanol or to one of
its constituents
188 N. Devereux et al.tumescent local anesthesia (TLA), routinely performed in
endovenous thermal procedures, does not only provide
anesthesia and disperses the generated heat, but also
compresses the target vein concentrically and ensures
minimal vessel diameter at the time of treatment.13 The
beneﬁt of pre-treatment size reduction with the aid of
tumescent application (TA) can also be used for catheter-
directed foam-sclerotherapy (CDFS) of truncal veins. CDFS
is a modiﬁcation of sclerotherapy, which allows safe treat-
ment of long varicose vessels using a single access point.
The combination of CDFS and peri-venous TLA was ﬁrst
recommended by Thibault,14 and further developed by
Parsi.13 To date, there have been no trial data published
about the combination of CDFS and TLA.Inﬂammational skin disorder
in punction area
Symptoms of mikroangiopathy
or neuropathy
Reduced general condition
High risk of deep vein
thrombosis (>three of the
following criteria):
oral contraceptive
obesity
smoking
immobility
Table 2. Baseline characteristics.
Baseline characteristics CDFS þ TA
(n ¼ 25)
CDFS (n ¼ 25)
Age, mean (range) 52.7 (20e83) 55.1 (26e80)
Female, n (%) 16 (64) 17 (68)
Left limb, n (%) 14 (56) 16 (64)
CEAP clinical grade
CEAP 2 11 (44) 11 (44)
CEAP 3 1 (4) 2 (8)Study objective
The aim of this study was to evaluate occlusion rates of
great saphenous veins (GSV) with a diameter between 5
and 10 mm that received pre-treatment size reduction with
the aid of perivenous TA followed by treatment with CDFS.
The primary objective was the occlusion rate 12 months
after performing CDFS in combination with TA in compari-
son to CDFS alone.
Secondary objectives concerned patient satisfaction with
treatment and symptom severity in both groups.
All data were assessed 1, 6, and 12 months after
treatment.
MATERIALS AND METHODS
Patients
The present study was designed as a single-centered, pro-
spective, randomized, blinded, pilot study with two groups.
After receiving ethical committee approval and approval
from the German Federal Institute for Drugs and Medical
Devices (BfArM; EudraCT-Nr. 2009-017472-25) the trial was
initiated in August 2010. Until August 2011, patients
attending the outpatient clinic of the Department of
Dermatology, University Luebeck, Germany, were screened
for inclusion in this study. Fifty patients with an incompe-
tent GSV and a diameter of 5e10 mm measured 3 cm distal
to the sapheno-femoral junction (SFJ) assessed by coloured
duplex ultrasound were enrolled. The detailed inclusion and
exclusion criteria are listed in Table 1. All patients were
given a copy of the written informed consent. The patients
were randomized into two groups, receiving either CDFS
with TA (group 1) or a treatment with CDFS alone (group 2).
Table 2 summarizes the baseline characteristics of the two
study groups.CEAP 4 13 (52) 11 (44)
CEAP 6 0 (0) 1 (4)
BMI, mean (range) 26.4 (20e36.1) 28.3 (20.0e45.8)
GSV diameter before
treatment in mm,
mean (range)
6.46 (5.0e9.7) 6.59 (5.0e9.6)
Note. CDFS ¼ cathether-directed foam scleropathy;
TA ¼ tumescent application; CEAP ¼ XXX; BMI ¼ body mass
index; GSV ¼ great saphenous vein.Diagnostics
Duplexsonography was performed with an HDI 5000 scan-
ner (Phillips, Solingen, Germany) using a 7.5-MHz trans-
ducer. The diameter was measured in supine position 3 cm
distal the SFJ. Further views of the GSV were captured at
mid-thigh-level, as well as below the knee. Those three
measuring points were controlled in all the follow ups.Treatment
Following the recommendations of our ethics committee
the CDFS treatments with or without tumescence were
performed under standardized conditions in supine position
in the operation centre of our clinic. The long angiography
catheter (Cavaﬁx Certo 355; FA Braun, Melsungen, Ger-
many) was introduced in to the GSV below the knee.
Through ultrasound guidance, the catheter was positioned
8 cm distal the SFJ and ﬁxated.
In group 1 a modiﬁed TLA, solely containing saline solu-
tion (0.9% sodium chloride) was performed and will be
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tumescent solutions (TLA) containing local anaesthetics and
adrenaline would not have been compatible with study
guidelines of the BfArM. The TA was strictly infused into the
saphenous fascia along the targeted vein under ultrasound
guidance by means of a peristaltic pump (Insufﬂation,
Medicon-Instruments, LS-I20, Tuttlingen, Germany) to ach-
ieve a fully compressed GSV (Fig. 1). A maximum of 500 mL
was in no case exceeded. Subsequently, 8 mL of 2% poli-
docanol foam (including 0.8 mL of foam left in the catheter),
prepared by using the EASY-FOAM kit (liquid:air ratio of
1.6:7.4; Laboratoire Kreussler Pharma, Paris, France) was
injected in both groups as the catheter was slowly
withdrawn.
Treatment was followed by a 24-hour eccentric
compression of the limb with rolled gauze pads along the
GSV and a thigh-length compression stocking class II. The
patient was advised to walk for 30 minutes. The stockings
were worn for 4 weeks after treatment during the daytime.
The procedure was performed each time by the same
surgeon (ND). Both patients and the investigators (ND, BK)
knew about the group selection; follow-up examinationsFigure 1. (a) Sonographic picture of great saphenous vein (GSV)
before perivenous tumescent application (TA); (b) GSV after
applying TA.were performed by two blinded investigators (ALR, LW). The
patients were asked not to tell the follow-up investigators
about the treatment they received.Follow up
Patients were seen 1, 6, and 12 months after treatment,
and assessed by blinded investigators. After clinical evalu-
ation, duplex ultrasound examination of the treated limb
was performed. Treatment outcome was classiﬁed by a two-
point grading system (Table 3) developed at the Second
European Consensus Meeting on Sclerotherapy at Tegern-
see.15 “Full success” (two points) was diagnosed when the
treated vein either fully disappeared, seen as a “ﬁbrous
cord”, was incompressible or if the vein diameter was
reduced and an antegrade reﬂux was seen. “Partial success”
(one point) was classiﬁed as a partial occlusion of the vein
in combination with vein diameter reduction and a reﬂux
<0.5 seconds. “No success” was classiﬁed as complete (or
incomplete) patency, no change in vein diameter and a
reﬂux >0.5 seconds. During follow up, no additional local
injection of foam was given.
At each visit patients were asked to rate the pain and
satisfaction with the treatment in a 5-point scale. The in-
vestigators looked for skin pigmentation, matting, and
thrombophlebitis.
At each visit, patients’ critical events, expected events,
and serious adverse events were assessed.Table 3. Duplex ultrasound and efﬁcacy criteria in foam
sclerotherapy from the second European consensus meeting on
foam sclerotherapy 2006.11
Grading/name Duplex
ﬁndings
2 points
full success
No reﬂux Complete disappearance
of the treated vein
or
“Fibrous cord” (incompressible
echogenic cord in the position
of the treated vein
Complete occlusion of the
treated vein segment
(incompressibility)
Patency of the treated vein
segment with reduced
diameter and antegrade ﬂow
1 point
partial
success
Reﬂux <0.5 s Partial incompressibility
and
Partial occlusion of treated
vein segment
and
diameter reduction
0 points
No success
Reﬂux >0.5 s
or unchanged
Complete (or incomplete)
patency
and/or
no change in diameter
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We obtained a sample size for the pilot trial using Fisher’s
exact test. The calculated sample size obtains 25 per group
(a ¼ 0.05, power ¼ 0.8) if the initial hypothesis assumed
100% success for the main outcome measure for CDFS þ TA
versus 70% for CDFS alone.Statistical methods
Statistical analysis was performed using SPSS Statistics version
20.0. Categorical variables are expressed as frequencies and
percentages, and continuous variables as the mean and SD.
For comparison between two groups with continuous vari-
ables, non-parametric ManneWhitney U-test was used. For
paired settings, a Wilcoxon rank sum test was used accord-
ingly. For tabulated categorical data, Fisher’s exact test was
used.To control formultiple testing, hypotheses were ordered
hierarchically. For parallel hypotheses at the same level of
hierarchy the BonferronieHolm procedure for was applied for
adjustment of p-values. Conﬁdence intervals for percentage
data were calculated according to Wilson. For raw and
normalized data the one sample t-test was used.
RESULTS
Patients
CDFS was technically successful in all the treated patients
(n ¼ 49/50). One patient in group 1 was excluded on the
ﬁrst visit owing to a serious adverse event (SAE), not related
to the treatment itself (see below). In one case, puncturing
the GSV was impossible owing to vasospasm; the patient
was successfully treated at a second appointment a week
later. After 12 months, one patient in group 1 and ﬁve
patients in group 2 were lost to follow-up (Fig. 2).Occlusion of the GSV
In the CDFS þ TA group, the 12-month duplex ultrasound
showed full occlusion in 17/23 (73.9%) patients, partial
occlusion in 2/23 (8.7%), and treatment failure in 4/23
(17.4%). In the CDFS alone group 15/20 (75%) of the tar-
geted GSV were fully occluded, 4/20 (20%) were partially
occluded, and 1/20 (5%) were classiﬁed as treatment fail-
ure. The proportion of successfully occluded veins after 1, 6,
and 12 months can be seen in Fig. 3. There were no sig-
niﬁcant inter-group differences.Diameter of the GSV
At 12-month follow-up there was a signiﬁcant reduction
(p < .005) of the treated GSV diameter of a mean of
2.76 mm (range, 0.3e7 mm) in the CDFS þ TA group and
3.18 mm (range, 0.6e6.2 mm) in the CDFS group. The
development of the GSV diameter in general (A) and
normalized to individualized starting data (B) are shown in
Fig. 4. There were no signiﬁcant inter-group differences.
Overall, 91.7% of the patients in the CDFS þ TA group and
90.5% in the CDFS alone group had a reduction in diameter
after 12 months.Patient satisfaction
Twelve months after treatment, patients in the CDFS þ TA
group retrospectively rated their satisfaction with the pro-
cedure as 4.65 (range, 3e5), on average, and in the CDFS
group as 4.32 (range, 1e5) on a scale of 1 (very unsatisﬁed)
to 5 (very satisﬁed). No inter-group differences were found
(Fig. 5). The overall combined rating of satisﬁed and very
satisﬁed was 95.7% in the CDFS þ TA group and 92% in the
CDFS group.
At 1-month follow up, patients in the CDFS þ TA group
reported pain during and after treatment (4.17, on average
[range, 3e5]), and in the CDFS alone group (4.08 [range, 3e
5]) on a scale of 1 (not tolerable) to 5 (no pain). No inter-
group differences were found (Fig. 6).
Adverse events and SAE
Table 4 shows the frequencies of matting, hyperpigmenta-
tion, and thrombophlebitis that occurred after treatment.
There were no signiﬁcant inter-group differences. In repeat
duplex ultrasound at each follow-up visit no sign of deep
vein thrombosis was seen. None of the patients reported
headaches or visual disturbances.
We reported three SAE. One patient in group 1 withdrew
owing to an episode of sudden tachycardia on the day of
the treatment, not related to the treatment itself. The
second patient, from group 2, was hospitalized with a
worsening of atopic eczema not related to the treatment.
The third patient, from group 2, reported numbness in his
left leg shortly after treatment. Symptoms were fully gone
after a few minutes, and the patient did not suffer any
permanent damage. The patient was referred to the
neurological clinic to exclude paradoxical clot embolism.
There was no sign of a fresh vascular lesion or paradoxical
emboli on computed tomography/magnetic resonance to-
mography. It was classiﬁed as microangiopathy. During
check-up a small patent foramen ovale (PFO), unknown to
the patient up to then, was found. Treatment was not
indicated.
DISCUSSION
In this randomized controlled study we investigated if there
was an improvement of the occlusion rates and general
outcomes using a combination of CDFS and TA to reduce
the diameter of the targeted vein.
During the 1990s, the ﬁrst concepts of sclerotherapy of
saphenous trunks using intravenous catheters were pub-
lished.16e21 The catheter technique offered an increase in
safety and efﬁcacy, in comparison with ultrasound guided
scleropathy (UGS).13 Since then, several modiﬁcations have
been developed to improve the outcome. Besides the use
of different catheter types, such as single lumen angiog-
raphy catheters with side holes or side slits and double-
lumen balloon catheters,2,13 different techniques to mini-
mize venous diameter or “empty the vein” before the
treatment in combination with CDFS have been described.
Milleret et al.22 reported a low recanalization rate of 3/60
(5%) 3 years after treating the GSV with a combination of
Figure 2. Study ﬂow diagram. Note. CDFS ¼ cathether-directed foam scleropathy; TA ¼ tumescent application.
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[STS] or 2% Polidocanol) and a pre-treatment by use of leg
elevation and bandaging of the leg, known as the “ALPHA
technique”. Brodersen and Geismar23 performed CDFS us-
ing a double-lumen that allowed the stoppage of bloodFigure 3. Means and 95% Wilson conﬁdence interval of successfully o
directed foam sclerotherapy (CDFS) in combination with tumescent apﬂow downstream of the SFJ, which, in turn, allowed a
better contact between vessel and sclerosant foam. They
achieved a 90% occlusion rate after 6 months. Another
promising method to enhance the outcome by “emptying
the vein” before the treatment, may be the pre-treatmentccluded veins 1, 6, and 12 months after treatment with catheter-
plication and CDFS alone. Note. TLA ¼ tumescent local anesthesia.
Figure 4. (A) Means and 95% Wilson conﬁdence interval of vein diameter of great saphenous vein measured 3 cm distal to the sapheno-
femoral junction 1, 6, and 12 months after treatment with catheter-directed foam sclerotherapy (CDFS) in combination with tumescent
application and CDFS alone. (B) Data normalized to individual vein diameter before treatment. Note. TLA ¼ tumescent local anesthesia.
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sion employing tumescent anesthesia into the saphenous
fascia.13,14 The technique has been described, but no trials
have been reported.Our results
In our study we initially evaluated promising high early oc-
clusion rates of 95.8% in the CDFSþ TA group and 92% in the
CDFS alone group after 1 month. The results concur with
earlier results of trials performing CDFS. Brodersen and
Geismar23 reported a 93% occlusion rate 1.5 months after
treatment with CDFS alone (3e4% Polidocanol, 8e12 mL).
One hundred percent occlusion rates 1 week after treatment
were evaluated by Kölbel et al.,24 Reich-Schupcke et al.25 and
Hahn et al.26 performing CDFS alone (3% Polidocanol, 5e
10 mL). Comparing those results with our data, no beneﬁt of
additional TA could be found. After 12 months in the
CDFS þ TA group 73.9% of the targeted GSV were fully
occluded, 8.7% were partly occluded, and 17.4% were clas-
siﬁed as treatment failure. In the CDFS alone group 75%
showed full occlusion, 20% partial occlusion, and 4% treat-
ment failure. Those results are in line with earlier resultsFigure 5. Patient satisfaction with treatment at 12 months follow-
up. Note. TLA ¼ tumescent local anesthesia.shown by Williamson et al.;27 the Swedish group treated 94
incompetent GSV with a maximum vein diameter of 10 mm
with CDFS (3% Polidocanol, 9.2 mL). They found occlusion in
70% after 1 year, 14% were partly occluded, and 15% were
recanalized. In comparison to several other studies, both of
the latter studies exclusively used a single treatment of GSV.
In both of our study groups we treated GSV with an average
diameter of 6.5 mm in supine position. It should be
mentioned that in the standing position the diameter of the
GSV is higher. This might be seen as a small ﬂaw in our results
considering that FS in GSV diameters of 5e6 mm showed
good efﬁcacy.28,29 Barrett et al.30 described good results in
veins up to 10 mm; however, in his study a mean number of
2.15 treatments utilizing an average of 8.37 mL of FS solution
(3% STS) were required to close all incompetent varicose
veins in the 10 mm group versus a mean of 2.8 treatments
and 13.9 mL foam (3% STS) for the >10 mm group.
In our study we evaluated the outcome of only one
treatment session with a limited foam volume of 8 mL.
None of our patients had further venous interventions
during follow up.
Referring to the literature we found similar efﬁcacy re-
sults of CDFS in both groups, such as those reported in
other studies where other access methods were used.7,8
Perhaps it may be concluded that the methods of
applying the foam are not as important as previously
assumed. In our study, we chose CDFS because it is
impossible to inject foam after tumescence is applied. It can
be speculated whether an interaction of foam with the
material of the plastic tube may be relevant for the efﬁcacy.
Concerning the catheter used in the study we found the
foam to be stable for >3 minutes in vitro.
In accordance with results described in previous studies
performing CDFS,23e27 patients in the present study were
highly satisﬁed with the treatment itself. No inter-group
differences could be found. In both groups, the satisfac-
tion rate was higher than the rate of successful treated GSV.
This phenomenon can be explained by the achieved
reduction of the diameter of the GSV in both groups. In
Figure 6. Post-treatment pain at 1 month follow-up. Note.
TLA ¼ tumescent local anesthesia.
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study we emphazised the measurements of the diameters
under standardized conditions in the relaxed supine posi-
tion. In our opinion, the advantages of the supine position
for the pre-treatment diagnostics are the reliability of the
data measured by different examiners and the assessment
of the accurate diameters of the GSV3 cm distant to the SFJ
in the treatment position of the patients by all examiners.
Similar results concerning patients satisfaction were
shown by Williamson et al.27 reporting that 84% of the
treated patients were satisﬁed, with an overall occlusion
rate of 70% a year after performing CDFS of the GSV.
Chapman-Smith and Browne33 reported a 4% clinical
recurrence rate 5 years after UGFS of the GSV, with 100%
patient acceptance of success. Serial annual duplex ultra-
sound demonstrated a signiﬁcant reduction in GSV and SFJ
diameters, maintained over time.33
Side effects and complications
Serious side effects of FS are estimated to be between 0%
and 5.7%. In a meta-analysis of 69 studies of treatment by
sclerotherapy for venous insufﬁciency systematic review of
FS, Jia et al.34 calculated a median incidence of 4.4% (range,
0e10.3%) for thrombophlebitis and 31.6% (range, 7.8e
55.1%) for matting/skin pigmentation. Studies performing
CDFS of the GSV reported similar results. Kölbel et al.24
diagnosed thrombophlebitis in 3/53 patients and Wil-
liamson et al.27 in 2/91 patients after CDFS of the GSV. In
the latter study, 26/91 patients showed pigmentation ofTable 4. Local side effects and thromboembolic complications.
Symptoms CDFS þ TLA
(n ¼ 23)
CDFS (n ¼ 20)
Matting n (%) 7 (30.4) 5 (25)
Hyperpigmentation n (%) 3 (13) 5 (25)
temporary n (%) 2 (8.7) 2 (10)
persistent n (%) 1 (4.3) 3 (15)
Thrombophlebitis n (%) 0 2 (10)
DVT after treatment 0 0
Note. CDFS ¼ cathether-directed foam scleropathy;
TA ¼ tumescent application; DVT ¼ deep vein thrombosis.some extent. In our study, thrombophlebitis and hyperpig-
mentation were less frequent in the CDFS þ TA group (0/23
and 3/23) than in the CDFS alone group (2/20 and 5/20).
Persistent hyperpigmentation was also more frequent in the
CDFS alone group (3/20). Overall, no signiﬁcant group dif-
ferences were observed. The fact that there was no occur-
rence of thrombophlebitis and less hyperpigmentation in
the CDFSþ TA group could be an indication for a preventive
effect on inﬂammatory side effects due to peri-venous TA.
Very rare, but signiﬁcant, complications following
sclerotherapy are cerebrovascular events. In a recent sys-
tematic review by Sarvananthan et al.,35 out of a total of
10,819 patients 21 cases of cerebrovascular accidents (CVA)
or transient ischaemic attacks (TIA) were reported, whereof
11 patients were found to have a right to left cardiac shunt,
usually a PFO. In our cohort, one patient reported numb-
ness in his left leg shortly after CDFS þ TA. The patient was
diagnosed with a small PFO, which was previously unknown
to both him and the investigators.
A PFO can be found in up to 30% in the general popu-
lation and in up to 51% in varicose patients.36,37 The
pathomechanism of the neurological symptoms is yet not
fully understood. Similar to our patient, in the majority of
patients with CVA or TIA a PFO or other right to left cardiac
shunt has been identiﬁed. It has been hypothesized that
foam bubbles in the cerebral circulation through a right-to-
left shunt (RLS) are the cause, even though foam bubbles in
the middle cerebral artery have also been observed on
transcranial Doppler in the absence of neurological com-
plications.35,38 Other proposed mechanisms suggest that
symptoms occur as a result of air embolus35,39 or as a re-
action to the sclerosant agent leading to vasospasm, mi-
graines and aura.38 The release of endothelin 1 is thought to
be a relevant discussion.40,41 Considering the high preva-
lence of PFO, the incidence of neurological complications
after foam sclerotherapy is relatively low, and experts do
not recommend a screening for RLS before FS treatment.11
No other serious adverse events in connection with the
treatment, such as DVT, visual disturbances, or anaphylaxis
were diagnosed in the present study.
Limitations
The main limitation of the present pilot study is the small
number of patients assessed Moreover, we believe that the
addition of adrenaline to the TA saline solution we used
might have achieved a more potent diameter reduction of
the targeted vein, while the adrenaline will induce a longer
and more consistent vasoconstriction.13 The application of
standard TA solution with adrenalin, lidocaine, and bicar-
bonate in this trial was not approved by the BfArM. Also,
during treatment, some patients in the CDFS þ TA group
experienced the application of saline TA as an uncomfort-
able and burning sensation.
Beneﬁts
To minimize bias, each treatment was performed by the
same investigator with an equal amount of volume and the
194 N. Devereux et al.same concentration for every patient. In this study, we
chose to limit the diameter of the GSV to 5e10 mm to
make the characteristics of the treated veins as homoge-
neous as possible. In comparison to most studies, patients
did not receive a second foam injection in case of recana-
lization within the 12 months of follow up (but patients
were later offered this option).
CONCLUSION
Tumescent application with saline to reduce the vein diam-
eter to aid the outcome of CDFS did not signiﬁcantly affect
the occlusion rates 12 months after treatment, which were
in the region of 74% in both study arms. It remains unan-
swered whether typical tumescent solutions containing local
anaesthetics and adrenaline could be more effective. As
such, a study design would not have been compatible with
study guidelines of the BfArm. Overall, the study was able to
demonstrate that CDFS is a safe and well tolerated treat-
ment that has a high rate of acceptance by the patients.
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